18 June 2024
In Russia, the first batch of a drug against ankylosing spondylitis with the active ingredient seniprutug went into public circulation. The Biocad company collaborated with scientists from the Pirogov Russian National Research Medical University and the Institute of Bioorganic Chemistry, named after the academicians M. M., to develop the product. Shemyakin and Yu. A. Ovchinnikov.
Ankylosing spondylitis is a type of arthritis that causes inflammation in the joints and ligaments of the spine. It may also affect peripheral joints like the knees, ankles, and hips.
In May, Russian Health Minister Mikhail Murashko announced that the medication would be available for sale in approximately three months, specifically in August. Additionally, he announced the inclusion of seniprutug in the list of vital and essential medicines.
Print06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
87% of cancer patients give positive ratings for medical care quality
18 September 2024
The Russian market of fillers and biorevitalizers grew by 21% in the first half of 2024
18 September 2024
Pharma’s Patient Reach Problem: Billions Still Left Behind
17 September 2024
17 September 2024